Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

Multiple Studies on Antiviral Treatment for Chronic Hepatitis B Selected for Conference Exchange, with a Focus on the Stability of Decompensation

From November 10th to 14th, 2023, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting was grandly held in Boston, USA. In this event, Dr. Wen Xie's team from Beijing Ditan Hospital, Capital Medical University, presented several notable research findings. One of them is a study on the stability of decompensation in patients with chronic hepatitis B and liver cirrhosis treated with entecavir (ETV) [1], which received the Outstanding Abstract Award at the conference. Hepatology Digest reports on these research findings as follows.
AASLD Voice of China | Dr. Zhenhuan Cao’s Team: The Impact of Hepatic Steatosis on Antiviral Therapy in Patients with Chronic Hepatitis B

AASLD Voice of China | Dr. Zhenhuan Cao’s Team: The Impact of Hepatic Steatosis on Antiviral Therapy in Patients with Chronic Hepatitis B

From November 10th to 14th, 2023, the annual highlight in the field of hepatology—the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023 was grandly held in Boston, USA. Dr. Zhenhuan Cao from Beijing You'an Hospital, Capital Medical University, as the corresponding author, presented a research abstract at the conference, revealing the influence of hepatic steatosis on the efficacy of antiviral therapy in patients with chronic hepatitis B (CHB). The results suggest that hepatic steatosis has no significant impact on the effectiveness of nucleos(t)ide analogs (NAs) and pegylated interferon (PEG-IFN) treatment [1]. Hepatology Digest reports on this, and the relevant content is shared below.